Table 3.
Clinical trial indicator | HT method | IT agent | Population | Phase | Status |
---|---|---|---|---|---|
NCT03757858 | RFA | ACT, ACT plus pembrolizumab, ACT plus standard CT, or standard CT | Adults with abdominal or pelvic malignancies or metastases | I/II | Recruiting |
NCT03393858 | RFA | ACT and pembrolizumab | Adults with advanced malignant mesothelioma | I/II | Recruiting |
ACT: adoptive T cell therapy; CT: chemotherapy; RFA: radiofrequency ablation.